APA (7th ed.) Citation

Shettle, L., McLaurin, E., Martel, J., Seaman, J. W., & Weissgerber, G. (2022). Topical Anti-TNFα Agent Licaminlimab (OCS-02) Relieves Persistent Ocular Discomfort in Severe Dry Eye Disease: A Randomized Phase II Study. Clinical ophthalmology (Auckland, N.Z.), 16, 2167-2177. https://doi.org/10.2147/OPTH.S366836

Chicago Style (17th ed.) Citation

Shettle, Lee, Eugene McLaurin, Joseph Martel, John W. Seaman, and Georges Weissgerber. "Topical Anti-TNFα Agent Licaminlimab (OCS-02) Relieves Persistent Ocular Discomfort in Severe Dry Eye Disease: A Randomized Phase II Study." Clinical Ophthalmology (Auckland, N.Z.) 16 (2022): 2167-2177. https://doi.org/10.2147/OPTH.S366836.

MLA (9th ed.) Citation

Shettle, Lee, et al. "Topical Anti-TNFα Agent Licaminlimab (OCS-02) Relieves Persistent Ocular Discomfort in Severe Dry Eye Disease: A Randomized Phase II Study." Clinical Ophthalmology (Auckland, N.Z.), vol. 16, 2022, pp. 2167-2177, https://doi.org/10.2147/OPTH.S366836.